You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Asthma
Symbicort Turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).
Chronic obstructive pulmonary disease (COPD)
Symbicort is indicated for the symptomatic treatment of moderate to severe COPD
(FEV1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator
use, and/or a history of recurrent exacerbations. Symbicort is not indicated for the initiation of
bronchodilator therapy in COPD.
Inhaler: The colour of the turning grip is red. On the turning grip a Braille code is embossed. The colour of the cover is white. Contents: The contents are white to off-white, predominantly in the form of rounded granules. More details on file.
Asthma
Symbicort Turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).
Chronic obstructive pulmonary disease (COPD)
Symbicort is indicated for the symptomatic treatment of moderate to severe COPD
(FEV1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator
use, and/or a history of recurrent exacerbations. Symbicort is not indicated for the initiation of
bronchodilator therapy in COPD.
Inhaler: The colour of the turning grip is red. On the turning grip a Braille code is embossed. The colour of the cover is white. Contents: The contents are white to off-white, predominantly in the form of rounded granules. More details on file.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Asthma
Symbicort Turbuhaler is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).
Chronic obstructive pulmonary disease (COPD)
Symbicort is indicated for the symptomatic treatment of moderate to severe COPD
(FEV1 < or = 50% predicted normal) in adults with frequent symptoms despite long-acting bronchodilator
use, and/or a history of recurrent exacerbations. Symbicort is not indicated for the initiation of
bronchodilator therapy in COPD.
Inhaler: The colour of the turning grip is red. On the turning grip a Braille code is embossed. The colour of the cover is white. Contents: The contents are white to off-white, predominantly in the form of rounded granules. More details on file.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
